Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.uniQure has entered into a non-exclusive cross-licensing agreement to gain access to Benitec's proprietary DNA-directed RNA interference (ddRNAi) technology to advance its research in the development of new therapies for Huntington's disease.
Subscribe to our email newsletter
In exchange, uniQure granted Benitec a non-exclusive access to its AAV5 delivery technology for the development of a ddRNAi therapy for Hepatitis B.
Benitec’s ddRNAi technology has the ability to silence the gene responsible for producing the mutant protein that is responsible for Huntington’s disease, claims uniQure.
Benitec Biopharma CEO Peter French said the uniQure has received market approval for a gene therapy product, Glybera, in the West, thus the company is pleased to execute the licensing agreement.
"uniQure have demonstrated their unique ability to take gene therapy-based programs from pre-clinical stages to commercialization, and we are confident that they will be able to achieve a similar outcome in this program," French added.